Drug Information

Drug General Information
Drug ID
D0S7HM
Former ID
DCL001071
Drug Name
ENMD-2076
Drug Type
Small molecular drug
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [531311], [542810]
Company
Entremed
Structure
Download
2D MOL

3D MOL
Formula
C21H25N7
InChI
InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
InChIKey
BLQYVHBZHAISJM-CMDGGOBGSA-N
PubChem Compound ID
16041424
PubChem Substance ID
24425674, 28680446, 41800685, 103652038, 104120140, 134339468, 136340301, 136920320, 137677350, 152258288, 160647127, 162011812, 163642938, 164194005, 174531559, 177748918, 180190841, 198971242, 223705105, 225255487, 226900028, 235457546, 240602867, 249565576, 252215348, 252451614
Target and Pathway
Target(s) Aurora kinase A Target Info Inhibitor [537564]
KEGG Pathway Oocyte meiosis
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M Transition
WikiPathways EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 531311ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10(1):126-37.
Ref 542810(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885).
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.